| | Agent | Name | Target | Type | FDA approval | Indication | Selected side effects | Clinical application |
| | Rituximab | Rituxan | CD20 | Chimeric | 1997 | B-cell NHL, CLL | Infusion related, fever, lymphopenia, neutropenia, susceptibility to infections, and progressive multifocal leukoencephalopathy | Agents currently clinically used |
| | Ibritumomab | Zevalin | CD20 | Mouse/radiolabeled | 2002 | B-cell NHL | Cytopenias, fatigue, nasopharyngitis, nausea, abdominal pain, asthenia, cough, diarrhea, and pyrexia | Agents currently clinically used |
| | Tositumomab | Bexxar | CD20 | Mouse/radiolabeled | 2003 | NHL | Neutropenia, thrombocytopenia, anemia, infections, infusion reactions, asthenia, fever, and nausea | Agents currently clinically used |
| | Ofatumumab | Arzerra | CD20 | Human | 2009 | CLL | Neutropenia, pneumonia, pyrexia, cough, diarrhea, anemia, fatigue, dyspnea, rash, nausea, bronchitis, and upper respiratory tract infections | Agents currently clinically used |
| | Gemtuzumab | Mylotarg | CD33 | Humanized/drug attached | 2000 | Relapsed AML | Infusion related, skin, and hepatotoxicity including the syndrome of venoocclusive disease | Withdrawn |
| | Brentuximab | Adcetris | CD30 | Chimeric/chemolabeled | 2011 | HL, sALCL | Neutropenia, peripheral sensory neuropathy, fatigue, nausea, anemia, upper respiratory infection, diarrhea, fever, cough, vomiting, and thrombocytopenia | Agents currently clinically used |
| | Alemtuzumab | Campath | CD52 | Humanized | 2001 | B-CLL | Cytopenias, infusion reactions, cytomegalovirus (CMV) and other infections, nausea, emesis, diarrhea, and insomnia | Agents currently clinically used |
| | Eculizumab | Soliris | C5 | Humanized | 2007 | PNH, aHUS | Hypertension, upper respiratory tract infection, diarrhea, headache, anemia, vomiting, nausea, urinary tract infection, and leucopenia | Agents currently clinically used |
|
|
